TG Therapeutics (TGTX) Tops Q3 EPS by $2.21, Beats on Revenue; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St rises as oil slide offers respite after Fed rate hike
- Oil falls 2% to one-week low as Middle East supply disruption fears ease
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Paradium AI (PAAI) Halted, News Pending
TG Therapeutics Reports Third Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance
November 3, 2025 7:01 AM ESTThird quarter 2025 total revenue of $161.7 million, including BRIUMVI U.S. net revenue of $152.9 million
Raises full year 2025 global revenue target to $600 million, and raises full year BRIUMVI U.S. net revenue target to approximately $585 million
Conference call to be held today, Monday, November 3, 2025, at 8:30 AM ETÂ Â Â
NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the third quarter of 2025, along with recent company developments, and provided an update on 2025 revenue guidance.
... More